, Volume 43, Issue 1, pp 41–47 | Cite as

Procalcitonin as an early diagnostic and monitoring tool in urosepsis following percutaneous nephrolithotomy

  • Ji Zheng
  • Qianwei Li
  • Weihua Fu
  • Jing Ren
  • Siji Song
  • Guoxian Deng
  • Jiwei Yao
  • Yongquan Wang
  • Weibing LiEmail author
  • Junan YanEmail author
Original Paper


To evaluate the value of procalcitonin (PCT) as an early marker for diagnosis and differentiation of without urosepsis, urosepsis, severe urosepsis, and uroseptic shock following PCNL and the ability of PCT to assess the effectiveness of antibiotic therapy in patients with urosepsis. From June 2012 to August 2013, 267 patients undergoing PCNL for renal calculi, and who fulfilled selection criteria, were recruited into our study. The patients’ medical records were reviewed retrospectively. One of selection criteria was the scores of PCT and WBC were collected at operative day, postoperative day one, day two, day three, day five and day seven. The area under the ROC curve for the prediction of urosepsis was 0.960 for PCT and 0.634 for WBC. PCT concentrations were higher in patients with uroseptic shock versus severe urosepsis versus urosepsis versus without urosepsis following PCNL. WBC values showed no significant difference between patients with urosepsis, severe urosepsis and uroseptic shock following PCNL. With time, in patients with successfully treated urosepsis following PCNL, the PCT concentrations significantly declined and kept decreasing from postoperative day two to postoperative day seven and the WBC scores showed no significant change over the first postoperative 2 days and were decreased only after postoperative day three. PCT appears to be a useful early marker to diagnosis and discriminate urosepsis, severe urosepsis and uroseptic shock following PCNL. Daily PCT measurements may be a valuable tool in monitoring the effectiveness of antibiotic therapy in urosepsis following PCNL.


Procalcitonin Urosepsis Percutaneous nephrolithotomy Diagnostic accuracy 




Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

Our retrospective study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.


  1. 1.
    Amer T, Ahmed K, Bultitude M, Khan S, Kumar P, De Rosa A, Khan MS, Hegarty N (2012) Standard versus tubeless percutaneous nephrolithotomy: a systematic review. Urol Int 88(4):373–382PubMedCrossRefGoogle Scholar
  2. 2.
    Lingeman JE, Matlaga BR, Evan AP (2007) Surgical management of upper urinary calculi. In: Campbell-Walsh WAJ, Kavoussi LR, Novisk AC, Partin AW, Peters CA (eds) Campbell’s urology. Elsevier, Saunders, p 1500Google Scholar
  3. 3.
    Charton M, Vallancien G, Veillon B, Brisset JM (1986) Urinary tract infection in percutaneous surgery for renal calculi. J Urol 135(1):15–17PubMedGoogle Scholar
  4. 4.
    O’Keeffe NK, Mortimer AJ, Sambrook PA, Rao PN (1993) Severe sepsis following percutaneous or endoscopic procedures for urinary tract stones. Br J Urol 72(3):277–283PubMedCrossRefGoogle Scholar
  5. 5.
    Rao PN, Dube DA, Weightman NC, Oppenheim BA, Morris J (1991) Prediction of septicemia following endourological manipulation for stones in the upper urinary tract. J Urol 146(4):955–960PubMedGoogle Scholar
  6. 6.
    Bag S, Kumar S, Taneja N, Sharma V, Mandal AK, Singh SK (2011) One week of nitrofurantoin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. Urology 77(1):45–49PubMedCrossRefGoogle Scholar
  7. 7.
    Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, Aldabo-Pallas T, Cayuela-Dominguez A, Marquez-Vacaro JA, Carbajal-Guerrero J, Garcia-Garmendia JL (2008) Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 61(2):436–441PubMedCrossRefGoogle Scholar
  8. 8.
    Moyer MW (2012) New biomarkers sought for improving sepsis management and care. Nat Med 18(7):999PubMedCrossRefGoogle Scholar
  9. 9.
    Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP (1995) The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273(2):117–123PubMedCrossRefGoogle Scholar
  10. 10.
    Wacker C, Prkno A, Brunkhorst FM, Schlattmann P (2013) Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 13(5):426–435PubMedCrossRefGoogle Scholar
  11. 11.
    Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B (2009) Effect of procalcitonin-based guidelines versus standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302(10):1059–1066PubMedCrossRefGoogle Scholar
  12. 12.
    Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Regnier B, Brun-Buisson C, Chastre J, Wolff M (2010) Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375(9713):463–474PubMedCrossRefGoogle Scholar
  13. 13.
    Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31(4):1250–1256PubMedCrossRefGoogle Scholar
  14. 14.
    Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R (2000) Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 26(Suppl 2):S148–S152PubMedCrossRefGoogle Scholar
  15. 15.
    Fioretto JR, Martin JG, Kurokawa CS, Carpi MF, Bonatto RC, de Moraes MA, Ricchetti SM (2010) Comparison between procalcitonin and C-reactive protein for early diagnosis of children with sepsis or septic shock. Inflamm Res 59(8):581–586PubMedCrossRefGoogle Scholar
  16. 16.
    Meisner M, Tschaikowsky K, Palmaers T, Schmidt J (1999) Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 3(1):45–50PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Ivancevic N, Radenkovic D, Bumbasirevic V, Karamarkovic A, Jeremic V, Kalezic N, Vodnik T, Beleslin B, Milic N, Gregoric P, Zarkovic M (2008) Procalcitonin in preoperative diagnosis of abdominal sepsis. Langenbecks Arch Surg 393(3):397–403PubMedCrossRefGoogle Scholar
  18. 18.
    Geppert A, Steiner A, Delle-Karth G, Heinz G, Huber K (2003) Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock. Intensive Care Med 29(8):1384–1389PubMedCrossRefGoogle Scholar
  19. 19.
    Guven H, Altintop L, Baydin A, Esen S, Aygun D, Hokelek M, Doganay Z, Bek Y (2002) Diagnostic value of procalcitonin levels as an early indicator of sepsis. Am J Emerg Med 20(3):202–206PubMedCrossRefGoogle Scholar
  20. 20.
    Ruiz-Alvarez MJ, Garcia-Valdecasas S, De Pablo R, Sanchez Garcia M, Coca C, Groeneveld TW, Roos A, Daha MR, Arribas I (2009) Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med 24(1):63–71PubMedCrossRefGoogle Scholar
  21. 21.
    Abdollahi A, Shoar S, Nayyeri F, Shariat M (2012) Diagnostic value of simultaneous measurement of procalcitonin, Interleukin-6 and hs-CRP in prediction of early-onset neonatal sepsis. Mediterr J Hematol Infect Dis 4(1):e2012028PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Heper Y, Akalin EH, Mistik R, Akgoz S, Tore O, Goral G, Oral B, Budak F, Helvaci S (2006) Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock. Eur J Clin Microbiol Infect Dis 25(8):481–491PubMedCrossRefGoogle Scholar
  23. 23.
    Aikawa N, Fujishima S, Endo S, Sekine I, Kogawa K, Yamamoto Y, Kushimoto S, Yukioka H, Kato N, Totsuka K, Kikuchi K, Ikeda T, Ikeda K, Harada K, Satomura S (2005) Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother 11(3):152–159PubMedCrossRefGoogle Scholar
  24. 24.
    Lavrentieva A, Papadopoulou S, Kioumis J, Kaimakamis E, Bitzani M (2012) PCT as a diagnostic and prognostic tool in burn patients. Whether time course has a role in monitoring sepsis treatment. Burns 38(3):356–363PubMedCrossRefGoogle Scholar
  25. 25.
    Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM (2011) Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. Am J Clin Pathol 135(2):182–189PubMedCrossRefGoogle Scholar
  26. 26.
    Vazzalwar R, Pina-Rodrigues E, Puppala BL, Angst DB, Schweig L (2005) Procalcitonin as a screening test for late-onset sepsis in preterm very low birth weight infants. J Perinatol 25(6):397–402PubMedCrossRefGoogle Scholar
  27. 27.
    Castelli GP, Pognani C, Cita M, Stuani A, Sgarbi L, Paladini R (2006) Procalcitonin, C-reactive protein, white blood cells and SOFA score in ICU: diagnosis and monitoring of sepsis. Minerva Anestesiol 72(1–2):69–80PubMedGoogle Scholar
  28. 28.
    Balc IC, Sungurtekin H, Gurses E, Sungurtekin U, Kaptanoglu B (2003) Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 7(1):85–90CrossRefGoogle Scholar
  29. 29.
    Charles PE, Ladoire S, Aho S, Quenot JP, Doise JM, Prin S, Olsson NO, Blettery B (2008) Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria. BMC Infect Dis 8:38PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Chiesa C, Panero A, Rossi N, Stegagno M, De Giusti M, Osborn JF, Pacifico L (1998) Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis 26(3):664–672PubMedCrossRefGoogle Scholar
  31. 31.
    Lapillonne A, Basson E, Monneret G, Bienvenu J, Salle BL (1998) Lack of specificity of procalcitonin for sepsis diagnosis in premature infants. Lancet 351(9110):1211–1212PubMedCrossRefGoogle Scholar
  32. 32.
    Karlsson S, Heikkinen M, Pettila V, Alila S, Vaisanen S, Pulkki K, Kolho E, Ruokonen E (2010) Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 14(6):R205PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Ji Zheng
    • 1
  • Qianwei Li
    • 1
  • Weihua Fu
    • 1
  • Jing Ren
    • 2
  • Siji Song
    • 1
  • Guoxian Deng
    • 1
  • Jiwei Yao
    • 1
  • Yongquan Wang
    • 1
  • Weibing Li
    • 1
    Email author
  • Junan Yan
    • 1
    Email author
  1. 1.Urological Surgery Research Institute, Southwest HospitalThird Military Medical UniversityChongqingChina
  2. 2.Service Center for Nursing, Southwest HospitalThird Military Medical UniversityChongqingChina

Personalised recommendations